The Schizophrenia Drugs Market is expected to reach US$ 10.47 billion by 2033 from US$ 7.68 billion in 2024, with a CAGR of 3.50% from 2025 to 2033. The rising incidence of schizophrenia and other ...

Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1s) was associated with lower risks of psychiatric ...

Schizophrenia is a complex mental health condition characterized by a disruption in a person’s thoughts, perceptions, emotions, and behavior. It can be a debilitating condition, but with proper ...

The FDA has given Motivista, a prescription digital therapeutic for adults with negative symptoms of schizophrenia, 510(k) ...

People with schizophrenia who were also taking GLP-1 drugs for diabetes had fewer psychiatric relapses in a large study of US ...

Israeli pharmaceutical giant Teva receives FDA approval for WELTRUZA, a new long-acting injection for schizophrenia that ...

For individuals diagnosed with schizophrenia, maintaining a daily medication routine can feel like an insurmountable challenge. The cognitive impairments associated with the disorder often interfere ...

Using a clock, virtual calendar, medication management app, or even a handwritten note, set a reminder to take your medication. If using a device, set the reminder to go off every day at the same time ...

GLP-1 use was also associated with fewer psychiatric emergency department visits. The association was observed mainly with ...

The general consensus among experts is that TRS is a condition in which an individual’s symptoms haven’t responded to two or more antipsychotic medicines given at a therapeutic dose for at least six ...